PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth of 41.00% while TRAW is zero. Bruce Berkowitz would see if minimal improvements could expand further.
27.93%
EBIT growth above 1.5x TRAW's 12.32%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.93%
Operating income growth above 1.5x TRAW's 12.32%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
29.77%
Net income growth above 1.5x TRAW's 11.71%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
30.61%
EPS growth above 1.5x TRAW's 13.04%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
30.61%
Diluted EPS growth above 1.5x TRAW's 13.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.13%
Share count expansion well above TRAW's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.13%
Diluted share count expanding well above TRAW's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
32.67%
OCF growth above 1.5x TRAW's 0.87%. David Dodd would confirm a clear edge in underlying cash generation.
32.86%
FCF growth above 1.5x TRAW's 1.18%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
10Y OCF/share CAGR at 75-90% of TRAW's 99.99%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
75.83%
5Y OCF/share CAGR at 75-90% of TRAW's 98.70%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
20.41%
3Y OCF/share CAGR under 50% of TRAW's 54.37%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
95.17%
Similar net income/share CAGR to TRAW's 99.99%. Walter Schloss would see parallel tailwinds or expansions for both firms.
79.59%
5Y net income/share CAGR at 75-90% of TRAW's 98.82%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
2.82%
Below 50% of TRAW's 63.34%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
170.99%
Positive growth while TRAW is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-42.91%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.55%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while TRAW invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.